KING: Important news this morning in the quest for COVID-19 vaccine, the pharmaceutical company Moderna hitting a milestone by finishing enrolling all of its trial, phase three trial participants. CNN senior medical correspondent Elizabeth Cohen joins us with more. Elizabeth, how significant?</s>ELIZABETH COHEN, CNN SENIOR MEDICAL CORRESPONDENT: John, it's significant before Moderna had been said that they would be ready or possibly ready to apply to the FDA for authorization to put this on the market. In December, I spoke with the president of the company Dr. Stephen Hoge. And he told me early December, so they're even more optimistic than they were before. Let's take a look at what's going to happen here. So 30,000 participants enrolled in the trial, they've all gotten their first shots, and most of them have gotten the booster shot that happens about a month later. Now remember, half of these people got the vaccine and half got the placebo and no one knows right now who got what. When 53 participants get sick with COVID-19 an analysis will be done, who the people who got sick, did they get the vaccine or the placebo? If at least 40 received the placebo, in other words, 75 percent, that means that Moderna will apply to the FDA for authorization. Now let's take a look at where all of these trials stand. As I said, Moderna says they could apply to the FDA in early December. Pfizer says they could apply to the FDA for emergency use authorization in late November AstraZeneca and Johnson & Johnson, John, those trials are both on hold. Participants one in each trial got sick. And so they've paused to see if they are going to go back or not. So those are both on pause right now. John?</s>KING: Elizabeth Cohen, grateful for that very important update. We'll stay on top of that. Coming up for us next, the race for the presidency, the battle for the control of the Senate, you want to look at one state to watch, how about North Carolina.
Moderna Reaches Target Of Enrolling 30,000 Participants For Phase 3 Of U.S. Vaccine trial.